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Abstract:  The antibacterial activity of 80% ethanol extracts of 10 medicinal plants 
collected in Yunnan (Southwest China), was tested against clinical isolates of extended-
spectrum β-lactamase (ESBL)-producing strains. Their MIC values ranged between   
1.56–12.50 mg/mL. The most active plant extract was Chelidonium majus L.  
(MIC = 1.56 mg/mL). Two potent isoquinoline alkaloids, 8-hydroxydihydrosanguinarine 
and 8-hydroxydihydrochelerythrine, were identified as the major active principles through 
bioassay-guided fractionation and identification of the active ethyl acetate fraction from   
C. majus, with minimum MIC/MBC values of 15.63/62.50 μg/mL. 
Keywords:  antibacterial plant extracts; ESBLs; 8-hydroxydihydrosanguinarine;   
8-hydroxydihydrochelerythrine 
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1. Introduction 
Extended-spectrum β-lactamases (ESBLs) are enzymes produced in some Gram-negative bacilli 
that mediate resistance to extended-spectrum antibiotics like cephalosporin and aztreonam. The first 
clinical isolates expressing acquired ESBLs were identified in Germany in 1983 [1]. ESBLs have the 
ability to hydrolyse and cause resistance to various types of the newer β-lactam antibiotics, including 
the expanded-spectrum (or third-generation) cephalosporins (e.g., cefotaxime, ceftriaxone, ceftazidime) 
and monobactams (e.g., aztreonam), but not the cephamycins (e.g., cefoxitin and cefotetan) and 
carbapenems (e.g., imipenem, meropenem, and ertapenem). They are most common in clinical isolates 
of  Escherichia coli and Klebsiella pneumoniae of the Enterobacteriaceae. The ESBL-producing 
multidrug-resistant (MDR) pathogens are  the  result of the selective pressure of currently used 
antibiotics and have been well recognized as a global nosocomial problem in recent years [2]. As 
plants can produce antimicrobial compounds to protect themselves from biotic attack, the search for 
antibacterial agents with different chemical structure and biological mode of action from plant sources 
is an alternative option in the fight against these microbes [3-5]. 
In the course of screening for active plant products against MDR bacteria, we paid special attention 
to the effects of Chinese medicinal plants on clinical isolates of ESBL-producing microorganisms. 
Here, we report the activities of ten plant extracts and two potent isoquinoline alkaloids   
8-hydroxydihydrosanguinarine (hhS, 1) and 8-hydroxydihydrochelerythrine (hhC, 2), obtained through  
bioassay-guided fractionation and identification from one of the active extracts of Chelidonium majus L. 
(bai-qu-cai in Chinese, [6]). 
2. Results and Discussion 
As shown in Table 1, various potencies against MDR and the ATCC control of E. coli were 
demonstrated by the tested extracts, with inhibitory zone diameters (IZDs) of 11.0–21.0 mm and MIC 
values of 1.56–12.50 mg/mL, respectively. Most of the extracts were active not only against MDR  
but also non-MDR strains of E. coli, which suggested the different mechanisms of effect and their 
potentials as alternative sources for combating the increasingly troublesome problem of bacterial 
infections in hospitals [2]. 
Bioassay-guided fractionation and isolation of an active extract from C. majus led to the 
identification of the 8-hydroxylated benzo[c]phenanthridine alkaloids hhS and hhC as the major active 
compounds. They showed potent activity against both clinical MDR isolates and ATCC control strains 
of E. coli, with the low MIC of 15.63 μg/mL (Figure 1 and Table 2). Other compounds in the active 
extracts are under investigation. 
From the results in Table 2, it is noted that though they were both phenotypic confirmatory   
ESBL-producing strains, the activity of hhS and hhC against such strains from E. coli were general 
much more active than those from K. pneumoniae. This could be attributed to the different resistance 
profiles of the two bacterial species with different genotypes [1,2]. 
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Table 1. IZD (mm) and MIC (mg/mL) of the crude extracts and active fractions against selected strains. 
No. Species  Family 
Speciesmen 
number 
Part 
a 
Ec 
b  Ec-MDR 
c 
IZD  MIC IZD  MIC 
1  Chelidonium majus L. Papaveraceae  KUN201236 Wp 20.0 1.56  15.0 3.12 
2 
Galla Chinensis 
(Rhus chinensis) 
Anacardiaceae KUN61317  W  16.0  3.12  13.0  6.25 
3 
Macleaya cordata 
(Willd.) R. Br. 
Papaveraceae KUN201093 Ap  21.0  3.12  14.0  3.12 
4 
Medinilla 
luchuenensis C. Y. 
Wu et C. Chen 
Melastomataceae KUN372 R  13.0  3.12  11.0  6.25 
5 
Michelia chapaensis 
Dandy 
Magnoliaceae KUN12152  Rh 15.0  3.12  12.0  6.25 
6  Myrsine africana L.  Myrsinaceae 
HITBC 
032831 
Ap 12.0  6.25  11.0  12.50 
7 
Paeonia lactiflora 
Pall. 
Ranunculaceae 
KUN 
365353 
R 16.0  3.12  13.0  3.12 
8 
Sagentodoxa cuneata 
(Oliv.) Rehd. et Wils. 
Sagentodoxaceae KUN3514 R  14.0  3.12  11.0 6.25 
9 
Eurya yunnanensis 
P.S. Hsu 
Theaceae YCP85965  Ap  11.0  12.50  NA 
d NA
 d 
10 
Viburnum foetidum 
Will. Var. foetidum 
Carprifoliaceae KUN287  Ap  NA 
d  NA
 d NA 
d NA 
d 
11  C. majus  Papaveraceae KUN201236 Fr-E  19.0  1.56  17.0  3.12 
12  C. majus  Papaveraceae KUN201236 Fr-E1  26.0  0.39  20.0  1.56 
13  C. majus.  Papaveraceae KUN201236 Fr-E2  22.0  0.78  19.0  1.56 
a Ap: aerial parts; F: fruits; R: roots; Rh: rhizome; Wp: whole plants; W: wart, Fr-E: ethyl acetate 
fraction; Fr-E1 and Fr-E2,: two sub-fractions of Fr-E; 
b Ec: E. coli (ATCC25922); 
c Ec-MDR: A 
total of five selected isolates of ESBLs-producing strains were tested; 
d NA: not active at 
concentrations up to 50 mg/mL. 
Figure 1. Structures of the four alkaloids (1: hhS; 2: hhC; 3: hS; 4: hC). 
 
 
 
 
 
C. majus has a long history in Chinese and European herbal medicine [6,7] as being useful for the 
treatment of many diseases. The present study reveals its in vitro anti-MDR activities against clinical 
isolates of ESBL-producing strains for the first time as far as we are aware [7,8]. It was found that 
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among the four tested alkaloids the 8-hydroxylated ones were generally more active than the non-
hydroxylated alkaloids. This type of alkaloids has been previously demonstrated to possess activity 
against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and resistant clinical 
yeast isolates [9,10]. Hence, they show broad-spectrum antimicrobial properties. However, to assess 
the efficacy and safety of these extracts and pure compounds, further in vitro and in vivo 
pharmacological assays are needed. 
Table 2. MICs and MBCs of the alkaloids and control agent for strains of clinical isolates. 
Strain and agent 
MIC (μg/mL )  MBC (μg/mL) 
Range  50% 90% Range  50%  90% 
Ec-MDR 
a             
hhS  15.63–250.0  31.25 125.0 62.50–500.0  62.50  250.0 
hhC  62.50–500.0  125.0 250.0 125.00–1000.0  125.0  500.0 
hS 750.0–3000.0
  1500 
d  3000 
d  NA 
d  NA 
d  NA 
d 
hC 1500.0–3000.0  3000 
d 3000 
d NA 
d NA 
d NA 
d 
imipenem  0.03–0.50 0.12 0.25 0.12-2.0  0.25  0.50 
K p-MDR 
b           
hhS  93.8–375.0 187.5 375.0 375.0–1500.0  750.0  1500.0 
hhC  187.5–750.0  187.5 375.0 375.0–1500.0  750.0  1500.0 
hS 750.0–3000.0
  1500 
d  3000 
d  NA 
d  NA 
d  NA 
d 
hC 1500.0–3000.0  3000 
d 3000
 d NA 
d NA 
d NA 
d 
imipenem  0.06–1.00 0.25 0.50 0.12–2.0  0.500  1.00 
Ec 
c    
hhS 15.63  31.25 
hhC 125.0  250.0 
hS 375.0  1500.0 
hC 375.0  1500.0 
imipenem 0.12  0.25 
a Ec-MDR: 18 isolates of ESBLs-producing strains from E. coli; 
b K p-MDR: 12 isolates of ESBLs-
producing strains from K. pneumonia; 
c Ec: E. coli (ATCC25922); 
d NA: not active at concentrations 
up to 3000 μg/mL. 
3. Experimental 
3.1. Plant Material 
Ten authenticated plant materials (Table 1) were collected in the mountainous Dali and Honghe 
districts of Yunnan Province, China, at attitudes of 600–2,500 m in September of 2007. They were 
identified by Shui Yuming of t he Kunming Institute of Botany, the Chinese Academy of Science 
(CAS, China) where voucher specimens were deposited. 
3.2. Bacterial Strains and Culture Media 
ESBL-producing MDR strains (18 from E. coli and 12 from K. pneumoniae isolates, respectively) 
were obtained from the infectious samples of critically ill patients at Kunming General Hospital Molecules 2011, 16                  
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(KGH). Pathogen purification and identification were conducted in the clinical microbiology 
laboratory of KGH following the standard procedures and the criteria of the Clinical and Laboratory 
Standards Institute (CLSI) [11-13]. Briefly, the isolates were initially screened using disks of 
ceftazidime (30 μg) and aztreonam (30 μg), and confirmed by using both ceftazidime and cefotaxime 
(30 μg), alone and in combination with clavulanic acid (10 μg). An isolate of a ≥5-mm increase in a 
zone diameter for either antimicrobial agent tested in combination with clavulanic acid compared with 
its zone when tested alone [e.g., ceftazidime zone = 16 mm; ceftazidime-clavulanic acid (30/10 μg) 
zone = 21 mm] was identified as an ESBL-producing isolate. The control strain ATCC 25922 (E. coli) 
was obtained from the National Institute for the Control of Pharmaceutical and Biological Products 
(NICPBP, China). Standard Mueller-Hinton agar and broth (MHA and MHB, Tianhe Microbial Agents 
Co., Hangzhou, China) were used as culture media. Imipenem (Merck & Co., Inc.) was used as the 
positive control agent. 
3.3. Extract Preparation and Isolation of the Active Compounds from C. majus Extracts 
The air-dried and ground plant material (30 g) was macerated with 80% ethanol (500 mL) for 5 days, 
filtered and the mare was further macerated twice with the same solvent overnight and filtered after 
being sonicated for 30 min. The filtrates were combined and the solvent was evaporated at 40 °C under 
vacuum. Ten extracts were prepared as a whole (Table 1). 
A larger sample (300 g) of active extract from C. majus (3 kg) was suspended in 600 mL of 
sterilized and deionated water and the suspension was successively fractionated between water and 
petroleum ether and AcOEt, of which the AcOEt fraction (Fr-E) showed the most activity in a 
bioassay-guided fractionation procedure. The fraction (25 g) was subjected to vacuum liquid 
chromatography over silica gel-H (500 mesh, Qingdao Haiyang Chemical Co., Ltd. Qingdao, China) 
and eluted with gradients of CHCl3–MeOH to afford two active fractions (Fr-E1 and Fr-E2), which 
were further purified by reverse-phase HPLC column chromatography to yield the two alkaloids 1 
(15.4 mg) and 2 (8.5 mg), respectively. Two other alkaloids, dihydrosanguinarine (hS, 3, 200 mg) and 
dihydrochelerythrine (hC, 4, 80 mg), were also obtained. All the spectral data were in agreement with 
the literature [14,15]. Their structures are shown in Figure 1. The MIC and MBC of the four alkaloids 
were determined accordingly at concentrations ranged from 0.003–3.0 mg/mL (Table 2). 
3.4. Susceptibility Test 
The ten extracts were first subjected to a susceptibility test of their IZD (mm) following the previous 
agar well diffusion method with a slight modification [16]. The inoculums were 1.5 × 10
8 CFU/mL 
suspensions and 70 μL aliquots of the extracts (50 mg/mL in 50% aqueous DMSO) were placed in  
6 mm (diam.) agar wells, incubated at 35 °C for 24 h. The MIC of the extracts (concentrations ranged 
from 0.5–50 mg/mL in 50% DMSO) for each organism were determined by the two-fold serial broth 
macro dilution method with MHB in tubes [12,16,17], with a slight modification as incubated at 35 °C 
for 24 h and each tube contained inoculums of 5 × 10
5 CFU/mL. All experiments were carried out in 
triplicate with 50% aqueous DMSO as the solvent control. The results are shown in Table 1. 
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4. Conclusions 
Ten Chinese medicinal plant extracts demonstrated varying levels of activity against clinical 
isolates of extended-spectrum β-lactamase (ESBL)-producing strains. Four alkaloids were identified 
from C. majus extracts, with 8-hydroxydihydrosanguinarine and 8-hydroxydihydrochelerythrine being 
the most active compounds. Their clinical utility against infections of ESBLs producers warrant further 
pharmacological investigations. 
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